Clinical trials: Peritoneum Cancer
Ovarian Cancer, Fallopian Tube Carcinoma
SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
This study is an open-label, dose-escalation, investigator-initiated phase I interventional clinical study. To evaluate the safety, tolerability and preliminary efficacy of SCT-001 CAR-T cell injection in subjects with relapsed…
- Conditions
- Ovarian Cancer, Fallopian Tube Carcinoma, Peritoneal Carcinoma
- Trial name
- NCT06846424
- Testing
- SCT-001 CAR-T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Ovarian Cancer, Fallopian Tube Cancer
Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer
This is a Phase 1 first in human, open label, multi-center, dose escalation study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-172154 in subjects with ovarian cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT04406623
- Testing
- SL-172154
- Where
- 6 sites in United States
- Volunteers
- 27 people
- Sponsor
- Shattuck Labs, Inc.
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer
RATIONALE: Estrogen can stimulate the growth of ovarian cancer cells. Hormone therapy using arzoxifene hydrochloride may fight ovarian or peritoneal cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00003670
- Testing
- arzoxifene hydrochloride
- Where
- 4 sites in United States
- Sponsor
- Eli Lilly and Company
Epithelial Ovarian Cancer, Extraovarian Peritoneal Cancer
A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
This study tests whether denileukin diftitox will deplete regulatory T cells, boost tumor-specific immunity and treat epithelial ovarian cancer in patients who have failed, or who are ineligible for front line therapy.
- Conditions
- Epithelial Ovarian Cancer, Extraovarian Peritoneal Cancer, Fallopian Tube Carcinoma
- Trial name
- ONTAK (NCT00880360)
- Testing
- Ontak
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
This is an open-label, phase 1/1b, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal…
- Conditions
- Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma
- Trial name
- PROTA (NCT05271318)
- Testing
- TILT-123, pembrolizumab, pegylated liposomal doxorubicin
- Where
- 3 sites in United States, Finland
- Volunteers
- 29 people
- Sponsor
- TILT Biotherapeutics Ltd.
Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced
Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
A study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme in patients with histologically proven advanced malignant pleural mesothelioma (MPM), advanced peritoneal mesothelioma (in dose escalation cohort…
- Conditions
- Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung Carcinoma, Uveal Melanoma
- Trial name
- TRAP (NCT02029690)
- Testing
- ADI-PEG 20
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 85 people
- Sponsor
- Polaris Group
Ovarian Cancer, Fallopian Tube Carcinoma
Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer
The purpose of this study is to define whether 6 courses of neoadjuvant chemotherapy can lead to a higher rate of complete cytoreductive surgery compared with 3 courses of neoadjuvant chemotherapy in patients with epithelial…
- Conditions
- Ovarian Cancer, Fallopian Tube Carcinoma, Peritoneal Carcinoma
- Trial name
- GOGER-01 (NCT02125513)
- Testing
- carboplatin and paclitaxel followed by surgery
- Where
- 5 sites in Italy
- Volunteers
- 129 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Ovarian Neoplasms, Peritoneal Neoplasms
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The purpose of this study is to assess the efficacy and safety of trabectedin+DOXIL as a third-line chemotherapy regimen (treatment) in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or…
- Conditions
- Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01846611
- Testing
- Trabectedin, DOXIL, Dexamethasone
- Where
- 138 sites in United States, Australia and 8 more
- Volunteers
- 581 people
- Sponsor
- Janssen Research & Development, LLC
Postoperative Cognitive Dysfunction
Risk Factors for Early POCD in the Patients With PSM Undergoing CRS-HIPEC
Objectives to investigate the incidence and associated factors for early postoperative cognitive dysfunction in the patients with peritoneal surface malignancies undergoing cytoreductive surgery and hyperthermic intraperitoneal…
- Trial name
- NCT02462564
- Where
- China
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Wuhan University
Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Up to 40 evaluable women with known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer will participate in two different imaging cohorts.
- Trial name
- NCT02637934
- Testing
- [18F]FluorThanatrace, PET/CT imaging sessions
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Recurrent Ovarian Cancer
Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer
The purpose of this randomized clinical study is to confirm the utility of chemosensitivity (ChemoID) tumor testing on cancer stem cells as a predictor of clinical response in recurrent epithelial ovarian cancer (EOC), fallopian…
- Trial name
- ACSCO (NCT03632798)
- Testing
- ChemoID assay, Chemotherapy
- Where
- 3 sites in United States
- Sponsor
- Cordgenics, LLC
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Ovarian Cancer, Fallopian Tube Cancer
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
Ovarian cancer is the leading cause of gynecologic cancer deaths, and the fifth most common cause of cancer deaths in women. While approximately 75% of patients with epithelial ovarian cancer will respond to first-line…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01610206
- Testing
- Gemcitabine, pazopanib
- Where
- 8 sites in United States
- Volunteers
- 148 people
- Sponsor
- Linda R Duska
Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
This phase I trial studies the side effects and best dose of intraperitoneal paclitaxel when given together with doxorubicin hydrochloride and cisplatin in treating patients with stage III-IV endometrial cancer.
- Conditions
- Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT00575952
- Testing
- Cisplatin, Doxorubicin Hydrochloride, Filgrastim
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer With Peritoneal Carcinosis
Extended Versus Short Prehabilitation Programme for Patients With Advanced Ovarian Cancer Undergoing Major Surgery
Standard treatment for advanced ovarian cancer includes a combination of cytotoxic chemotherapy and citorreductive surgery. During neo-adjuvant administration of chemotherapy, many patients experience a decline in their…
- Trial name
- SOPHIE II (NCT07509814)
- Testing
- Extended (Long)-Prehabilitation, Standard (Short)-Prehabilitation
- Where
- 5 sites in Spain
- Volunteers
- 225 people
- Sponsor
- Hospital Clinic of Barcelona
Colorectal Cancer, Peritoneal Cancer
Detecting Activity to Support Healing
The goal of this research is to develop and test a technology-supported intervention to reduce sedentary behavior before and after cancer surgery.
- Conditions
- Colorectal Cancer, Peritoneal Cancer, Sedentary Lifestyle
- Trial name
- DASH (NCT03211806)
- Testing
- Sedentary Behavior, Bluetooth-enabled activity monitor
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Pittsburgh
Carcinomatosis, Peritoneal
Inferior Epigastric Lymp Node (IELN) Basin as a Possible Systemic Metastatic Pathway of Ovarian Peritoneal Metastases
The IELN basin could represent a primary LN relay for systemic metastatic dissemination in patients with OPM. This newly described lymphatic pathway of metastatic dissemination of OPM may be involved in certain presentations of…
- Trial name
- OvEpiLyPath (NCT06237582)
- Testing
- epigastric lymph node biopsy
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Jules Bordet Institute
Ovarian Cancer
ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab
This is a phase III, randomized, double-blinded, comparative, multi-centre study to assess the efficacy of atezolizumab in combination with platinum-based chemotherapy plus bevacizumab administered concurrent to chemotherapy and…
- Trial name
- ATALANTE (NCT02891824)
- Testing
- atezolizumab + avastin + platinum-based chemotherapy
- Where
- 75 sites in Austria, Belgium and 5 more
- Volunteers
- 614 people
- Sponsor
- ARCAGY/ GINECO GROUP
Ovarian Carcinoma, Stage 3 or 4, Epithelial Ovarian Carcinoma
N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer
RATIONAL FOR STUDYING IV NAC AS POTENTIAL CHEMOPROTECTANT: Cisplatin has shown efficacy in the treatment of subjects with epithelial ovarian cancer.
- Conditions
- Ovarian Carcinoma, Stage 3 or 4, Epithelial Ovarian Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT01138137
- Testing
- Paclitaxel, N-acetylcysteine, Cisplatin
- Where
- United States
- Sponsor
- OHSU Knight Cancer Institute
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Total/Subtotal Colectomy in Ovarian Cancer
The purpose of this study is to evaluate the safety and one year disease-free survival of total or subtotal colectomy and proctocolectomy in stage IIIc and stage IV epithelial ovarian, fallopian tube, and primary peritoneal…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Secondary Malignant Neoplasm of Large Intestine
- Trial name
- NCT02595021
- Testing
- Total or Subtotal Colectomy, Other Bowel Resection
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shanghai Gynecologic Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.